Vimnerixin
Based on 1 Customer Validation
Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease.
For research use only. We do not sell to patients.
- Purity : 99.16%
- CAS No.: 1418112-77-2
- Formula: C19H25FN4O5S2
- Molecular Weight:472.55
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-16711
SB225002CXCR2 Antagonist -
HY-15319
AMG 487CXCR3 Antagonist -
HY-15251
ReparixinCXCR1/2 Inhibitor -
HY-10198
NavarixinCXCR1/2 Antagonist -
HY-19855
AZD-5069CXCR2 Antagonist -
HY-50688
SB-265610CXCR2 Antagonist -
HY-15252
Reparixin L-lysine saltCXCR Inhibitor -
HY-119339
SX-682CXCR1/2 Inhibitor -
HY-10017
SCH 546738CXCR3 Antagonist -
HY-12488
LY2510924CXCR Inhibitor -
HY-15320
NBI-74330CXCR Antagonist -
HY-15478
WZ811CXCR4 Antagonist
Biological Activity
Description
IC50 & Target
CXCR2[1]
In Vivo
.
| In Vivo PK | Rat | Dog |
| Predicted hepatic metabolic CL (ml/min per kilogram) | 1.7 | 0.80 |
| Observed CL (ml/min per kilogram) | 2.4 | 0.50 |
| CLrenal (mL/min per kilogram) | <0.01 | <0.01 |
| CLbiliary (mL/min per kilogram) | <0.01 | 0.04 |
| In vivo/in vitro unbound CLintc | 1.4 | 0.6 |
| VSS (l/kg) | 0.19 | 0.15 |
| T1/2 (h) (PO) | 1.3 | 3.7 |
| (2.7) | (8.4) | |
| F (%) | 45 | 82 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1418112-77-2
-
Appearance Solid
-
Molecular Weight 472.55
-
Formula C19H25FN4O5S2
-
Color White to off-white
-
SMILES
O=S(NC1=NC(SCC2=CC=C(C=C2)F)=NC(O[C@H](C)[C@@H](O)CO)=C1)(N3CC(C3)C)=O
-
Synonyms
AZD4721; RIST4721
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (211.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1162 mL | 10.5809 mL | 21.1618 mL | 52.9045 mL |
| 5 mM | 0.4232 mL | 2.1162 mL | 4.2324 mL | 10.5809 mL | |
| 10 mM | 0.2116 mL | 1.0581 mL | 2.1162 mL | 5.2904 mL | |
| 15 mM | 0.1411 mL | 0.7054 mL | 1.4108 mL | 3.5270 mL | |
| 20 mM | 0.1058 mL | 0.5290 mL | 1.0581 mL | 2.6452 mL | |
| 25 mM | 0.0846 mL | 0.4232 mL | 0.8465 mL | 2.1162 mL | |
| 30 mM | 0.0705 mL | 0.3527 mL | 0.7054 mL | 1.7635 mL | |
| 40 mM | 0.0529 mL | 0.2645 mL | 0.5290 mL | 1.3226 mL | |
| 50 mM | 0.0423 mL | 0.2116 mL | 0.4232 mL | 1.0581 mL | |
| 60 mM | 0.0353 mL | 0.1763 mL | 0.3527 mL | 0.8817 mL | |
| 80 mM | 0.0265 mL | 0.1323 mL | 0.2645 mL | 0.6613 mL | |
| 100 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5290 mL |
Vimnerixin Related Classifications
HY-145640 Related Classifications
Powered by Bioz